TumCMig Cancer Research Results
TumCMig, Tumor cell migration: Click to Expand ⟱
| Source: |
| Type: |
Tumor cell migration is a critical process in cancer progression and metastasis, which is the spread of cancer cells from the primary tumor to distant sites in the body.
|
Ovarian, Ovarian Cancer: Click to Expand ⟱
Scientific Papers found: Click to Expand⟱
| - |
vitro+vivo, |
Ovarian, |
NA |
|
|
|
antiNeop↑, TumCP↓, TumCMig↓, TumCI↓, TumCG↓, miR-375↑, IGFR↓, Snail↓, E-cadherin↑,
| - |
in-vitro, |
Ovarian, |
MDAH-2774 |
|
|
|
TumCP↓, TumCI↓, TumCMig↓, Apoptosis↑, ROS↑, miR-21↓, miR-130a↓, Casp8∅, Casp10∅, cycD1/CCND1∅, CDK6∅, CDK4∅, FADD∅, DR4∅, DR5∅,
| - |
in-vitro, |
Ovarian, |
SKOV3 |
|
|
|
- |
in-vitro, |
Ovarian, |
OVCAR-3 |
|
|
|
TumCMig↓, TumCI↓, NF-kB↓, p65↓, MMP9↓, eff↑, AntiTum↑, Inflam↓, AntiDiabetic↑,
| - |
vitro+vivo, |
Ovarian, |
SKOV3 |
|
|
|
- |
in-vitro, |
Ovarian, |
A2780S |
|
|
|
TumCP↓, TumCMig↓, TumCI↓, EMT↓, N-cadherin↓, Vim↓, E-cadherin↑, TumCG↓, CD133↓, OCT4↓, CSCs↓,
tumCV↓, Apoptosis↑, Casp3↑, Casp9↑, Bax:Bcl2↑, TumCMig↓, TumCI↓, MMP2↓, MMP9↓, p‑ERK↓,
| - |
in-vitro, |
Ovarian, |
A2780S |
|
|
|
- |
in-vitro, |
Ovarian, |
SKOV3 |
|
|
|
Dose↝, TumCP↓, Apoptosis↑, TumCMig↓, TumCI↓, TumVol↓, p‑STAT3↓, p‑ERK↓, IR↓,
| - |
in-vitro, |
Ovarian, |
OVCAR-3 |
|
|
|
*Inflam↓, *AntiBio↑, *antiOx↑, TumCMig↓, AKT1↓, cycD1/CCND1↓,
| - |
in-vitro, |
Ovarian, |
SKOV3 |
|
|
|
ROS↑, CSCs↓, CD44↓, SOX2↓, cMyc↓, TumMeta↓, TumCI↓, TumCMig↓, CD133↓, Nanog↓,
| - |
vitro+vivo, |
Ovarian, |
NA |
|
|
|
MAPK↓, ERK↓, PI3K↓, Akt↓, p‑PARP↑, cl‑Casp3↑, Bax:Bcl2↑, TumCMig↓, SMAD3↓,
| - |
in-vitro, |
Ovarian, |
A2780S |
|
|
|
- |
in-vivo, |
NA, |
NA |
|
|
|
TumCP↓, TumCMig↓, PI3K↓, TumVol↓, TumW↓, BioAv↑, GutMicro↑, Dose∅, eff↑, EGFR↓, cycD1/CCND1↓, toxicity∅,
| - |
in-vitro, |
Ovarian, |
SKOV3 |
|
|
|
TumCMig↓, TumCI↓, MDA↑, ROS↑, BAX↑, Casp3↑, Bcl-2↓, SREBP1↓, FASN↓, AMPK↓, p‑AMPK↑, p‑P53↑, p‑TSC2↑, p‑Akt↓, p‑mTOR↓, p‑S6K↓, p‑4E-BP1↓,
TumCI↓, E-cadherin↑, N-cadherin↓, Vim↓, Wnt↓, β-catenin/ZEB1↓, TumCP↓, TumCMig↓, EMT↓,
Showing Research Papers: 1 to 12 of 12
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 12
Pathway results for Effect on Cancer / Diseased Cells:
NA, unassigned(tgid=0) ⓘ
miR-375↑, 1,
Redox & Oxidative Stress(tgid=1) ⓘ
MDA↑, 1, ROS↑, 3,
Core Metabolism/Glycolysis(tgid=4) ⓘ
AKT1↓, 1, AMPK↓, 1, p‑AMPK↑, 1, cMyc↓, 1, FASN↓, 1, IR↓, 1, p‑S6K↓, 1, SREBP1↓, 1,
Cell Death(tgid=5) ⓘ
Akt↓, 1, p‑Akt↓, 1, Apoptosis↑, 3, BAX↑, 1, Bax:Bcl2↑, 2, Bcl-2↓, 1, Casp10∅, 1, Casp3↑, 2, cl‑Casp3↑, 1, Casp8∅, 1, Casp9↑, 1, DR4∅, 1, DR5∅, 1, FADD∅, 1, MAPK↓, 1,
Kinase & Signal Transduction(tgid=6) ⓘ
p‑TSC2↑, 1,
Transcription & Epigenetics(tgid=7) ⓘ
miR-21↓, 1, tumCV↓, 1,
DNA Damage & Repair(tgid=10) ⓘ
p‑P53↑, 1, p‑PARP↑, 1,
Cell Cycle & Senescence(tgid=11) ⓘ
CDK4∅, 1, cycD1/CCND1↓, 2, cycD1/CCND1∅, 1,
Proliferation, Differentiation & Cell State(tgid=12) ⓘ
p‑4E-BP1↓, 1, CD133↓, 2, CD44↓, 1, CSCs↓, 2, EMT↓, 2, ERK↓, 1, p‑ERK↓, 2, IGFR↓, 1, p‑mTOR↓, 1, Nanog↓, 1, OCT4↓, 1, PI3K↓, 2, SOX2↓, 1, p‑STAT3↓, 1, TumCG↓, 2, Wnt↓, 1,
Migration(tgid=13) ⓘ
E-cadherin↑, 3, miR-130a↓, 1, MMP2↓, 1, MMP9↓, 2, N-cadherin↓, 2, SMAD3↓, 1, Snail↓, 1, TumCI↓, 9, TumCMig↓, 12, TumCP↓, 6, TumMeta↓, 1, Vim↓, 2, β-catenin/ZEB1↓, 1,
Angiogenesis & Vasculature(tgid=14) ⓘ
EGFR↓, 1,
Immune & Inflammatory Signaling(tgid=16) ⓘ
Inflam↓, 1, NF-kB↓, 1, p65↓, 1,
Hormonal & Nuclear Receptors(tgid=20) ⓘ
CDK6∅, 1,
Drug Metabolism & Resistance(tgid=21) ⓘ
BioAv↑, 1, Dose↝, 1, Dose∅, 1, eff↑, 2,
Clinical Biomarkers(tgid=22) ⓘ
EGFR↓, 1, GutMicro↑, 1,
Functional Outcomes(tgid=23) ⓘ
AntiDiabetic↑, 1, antiNeop↑, 1, AntiTum↑, 1, toxicity∅, 1, TumVol↓, 2, TumW↓, 1,
Total Targets: 80
Pathway results for Effect on Normal Cells:
NA, unassigned(tgid=0) ⓘ
AntiBio↑, 1,
Redox & Oxidative Stress(tgid=1) ⓘ
antiOx↑, 1,
Immune & Inflammatory Signaling(tgid=16) ⓘ
Inflam↓, 1,
Total Targets: 3
Scientific Paper Hit Count for: TumCMig, Tumor cell migration
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:20 Cells:% prod#:% Target#:326 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid
Home Page